| Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised … FJ Raal, RD Santos, DJ Blom, AD Marais, MJ Charng, WC Cromwell, ... The Lancet 375 (9719), 998-1006, 2010 | 1067 | 2010 |
| Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents: a comparative analysis TA Vickers, S Koo, CF Bennett, ST Crooke, NM Dean, BF Baker Journal of Biological Chemistry 278 (9), 7108-7118, 2003 | 792 | 2003 |
| RNA-targeted therapeutics ST Crooke, JL Witztum, CF Bennett, BF Baker Cell metabolism 27 (4), 714-739, 2018 | 757 | 2018 |
| Antisense oligonucleotides targeting apolipoprotein (a) in people with raised lipoprotein (a): two randomised, double-blind, placebo-controlled, dose-ranging trials NJ Viney, JC van Capelleveen, RS Geary, S Xia, JA Tami, ZY Rosie, ... The Lancet 388 (10057), 2239-2253, 2016 | 747 | 2016 |
| Progress in antisense technology ST Crooke Annu. Rev. Med. 55 (1), 61-95, 2004 | 718 | 2004 |
| Oligoribonucleotides and ribonucleases for cleaving RNA ST Crooke US Patent 6,107,094, 2000 | 696 | 2000 |
| Antisense drug technology: principles, strategies, and applications ST Crooke CRC press, 2007 | 634 | 2007 |
| Mitomycin C: a review ST Crooke, WT Bradner Cancer treatment reviews 3 (3), 121-139, 1976 | 630 | 1976 |
| Molecular mechanisms of action of antisense drugs ST Crooke Biochimica et Biophysica Acta (BBA)-Gene Structure and Expression 1489 (1 …, 1999 | 628 | 1999 |
| Therapeutic applications of oligonucleotides ST Crooke Bio/technology 10 (8), 882-886, 1992 | 614 | 1992 |
| Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II FH Drake, GA Hofmann, HF Bartus, MR Mattern, ST Crooke, CK Mirabelli Biochemistry 28 (20), 8154-8160, 1989 | 605 | 1989 |
| Oligoribonucleotides for cleaving RNA ST Crooke US Patent 5,898,031, 1999 | 600 | 1999 |
| Cisplatin (cis-diamminedichloroplatinum II) AW Prestayko, JC D'aoust, BF Issell, ST Crooke Cancer treatment reviews 6 (1), 17-39, 1979 | 574 | 1979 |
| Cellular uptake and trafficking of antisense oligonucleotides ST Crooke, S Wang, TA Vickers, W Shen, X Liang Nature biotechnology 35 (3), 230-237, 2017 | 517 | 2017 |
| Antisense research and applications ST Crooke, B Lebleu CRC Press, 1993 | 509 | 1993 |
| Inhibition of proteolysis and cell cycle progression in a multiubiquitination-deficient yeast mutant D Finley, S Sadis, BP Monia, P Boucher, DJ Ecker, ST Crooke, V Chau Molecular and cellular biology 14 (8), 5501-5509, 1994 | 505 | 1994 |
| Antisense technology: an overview and prospectus ST Crooke, BF Baker, RM Crooke, X Liang Nature reviews Drug discovery 20 (6), 427-453, 2021 | 501 | 2021 |
| Progress in antisense oligonucleotide therapeutics. ST Crooke, CF Bennett Annual Review of Pharmacology and Toxicology 36, 107-129, 1996 | 485 | 1996 |
| Evaluation of the in Vivo Antitumor Activity and in Vitro Cytotoxic Properties of Auranofin, a Coordinated Gold Compound, in Murine Tumor Models CK Mirabelli, RK Johnson, CM Sung, L Faucette, K Muirhead, ST Crooke Cancer research 45 (1), 32-39, 1985 | 429 | 1985 |
| Pharmacokinetic properties of several novel oligonucleotide analogs in mice. ST Crooke, MJ Graham, JE Zuckerman, D Brooks, BS Conklin, ... Journal of Pharmacology and Experimental Therapeutics 277 (2), 923-937, 1996 | 424 | 1996 |
David J EckerIonis PharmaceuticalsEmail verificata su ionisph.com